Frequently Asked Questions

Health Law Alliance is pleased to announce the successful resolution of numerous federal and state cases involving significant inventory shortfalls, including the dismissal of criminal charges and civil settlements for fractions of the dollar amount on claims paid.

As discussed below, Health Law Alliance (HLA)’s attorneys specialize in the defense of PBM audits and inventory discrepancies. We could not be more pleased to obtain the outcomes discussed below on behalf of clients.

PBM Audit Case Study #1

Commonwealth of Massachusetts v. Pharmacy & Owner. Following a PBM audit that noted significant inventory discrepancies, the State of Massachusetts Attorney General's Office opened an investigation.

After a lengthy investigation, Owner and pharmacy were both indicted and charged with criminal offenses that carried penalties involving lengthy prison sentences and exclusion. The 14-count indictments alleged that Owner billed Medicaid and other insurance plans almost $500,000 for 37,000 units of Zegerid, a heartburn medicine, even though the pharmacy's records indicated that the pharmacy had only purchased 12,000 units, a discrepancy of 25,000 units.

In addition, the indictments charged Owner with crimes relating to the dispensing of controlled substances, including accepting cash for prescriptions covered by MassHealth.

Following the criminal charges, the HLA team determined that the best strategy was to win in court, and pushed for an immediate trial. As a result of HLA's work, the Attorney General's Office dismissed all 14 counts in both indictments completely, permitted the pharmacy to remain in network, and did not exclude Owner.

PBM Audit Case Study #2

United States v. Pharmacy & Owner: Following PBM audits that noted inventory discrepancies, the U.S. Attorney's Office for the Eastern District of Pennsylvania, DEA and HHS-OIG opened an investigation.

After a review of the evidence, federal prosecutors alleged that Owner and his pharmacies had billed Medicare for approximately $6.5 million in compound creams across multiple pharmacies even though the pharmacy’s records indicated that they had never purchased the APIs in those creams.

In addition, the government alleged that Owner had violated laws relating to controlled substances, including Schedule II substances.

Following these threatened charges, the HLA team determined that the best strategy was to convince federal prosecutors not to file criminal charges and resolve the case. As a result of HLA's work, Owner was not charged criminally and instead settled the matter civilly for $2.5 million (62% less than the alleged discrepancy), admitted no wrongdoing, and was not excluded.

PBM Audit Case Study #3

Commonwealth of Pennsylvania v. Pharmacy & Owner: Following PBM audits that noted inventory discrepancies, the State of Pennsylvania Attorney General's Office opened an investigation.

After a lengthy investigation, the Attorney General moved to indict both the pharmacy and Owner on criminal felony charges for billing Medicaid nearly $600,000 for dispensing medications that were never provided to customers, either because the pharmacy never had them in stock or had sold them to another company for financial gain.

After analyzing the case, our HLA team determined that the best strategy was to negotiate the most favorable resolution possible. As a result of HLA's work, the Attorney General's Office declined prosecution of Owner, a particularly noteworthy accomplishment given his citizenship status.

Instead, as part of the settlement, the Attorney General's Office agreed to charge the corporate entity, which permitted Owner to avoid criminal charges and exclusion. Happily, Owner now can look forward to a life in this country with his family.

HLA Specializes in PBM Audit Defense

Finally, please note that the above cases are public matters, and HLA cannot discuss the numerous other inventory cases that have been resolved successfully before they became public. Here, at the Health Law Alliance, our firm’s mission is simple: use unmatched experience and insight to defend our clients against insurance conglomerates, the federal government, and state agencies. We used to work for them. Now let us fight for you. Contact us today for a consultation. We can help.

MORE ARTICLES BY CATEGORY

Get a Free Case REVIEW

100% Confidential & Secure. Your details are safe with us.

We'll speak soon!

In the meantime, why not find out more about us or visit our blog.

Alternatively, give us a call at (800) 345 - 4125

Oops! Something went wrong while submitting the form.

HLA's Diana Yastrovskaya Featured in PBM Discussion for WJAC

The feature underscores HLA’s mission to elevate thought leadership within the healthcare space and provide trusted expertise on issues that directly impact patients, providers, and policymakers.

Read More >>

By Appointment Only: How DME Suppliers Can Prevent Unexpected DME License Revocations

DME suppliers can prevent unexpected and costly license revocations by strategically applying with a "By Appointment Only" designation. This article explores the common compliance trap of failing unannounced site visits due to conflicts between standard pharmacy operating hours and Medicare's "posted hours" requirement for DME suppliers. "By Appointment Only" status is a crucial safeguard, which suppliers can take to implement to protect their DME billing privileges.

Read More >>

Resolving Prescription “Red Flags” Is No Longer Optional: Federal Scrutiny Tightens on Controlled-Substance Dispensing

Pharmacists must resolve “red flags” under the Controlled Substances Act’s corresponding-responsibility requirements before dispensing controlled substances. Overlooking warning signs, such as cash-paid, high-dose opioid prescriptions—can now trigger False Claims Act liability and massive penalties, as demonstrated by Walgreens’ $350 million settlement in April 2025.

Read More >>

9th Circuit’s Landmark EKRA Ruling—What Providers Should Know

On July 11, 2025, the 9th Circuit upheld a laboratory operator’s convictions for violating EKRA by paying marketing agents to mislead providers into providing patient referrals for medically unnecessary blood tests. In this article, we analyze the 9th Circuit’s ruling and what it means for the future of EKRA enforcement.

Read More >>